赛升药业实控人方拟套现约1.2亿 去年亏损前年扣非亏

Group 1 - The core point of the news is that Sai Sheng Pharmaceutical (300485.SZ) announced a share reduction plan by its controlling shareholders and actual controllers' concerted actors, Ma Li and Liu Shuqin, who plan to reduce their holdings by up to 9,633,328 shares, representing 2% of the total share capital [1] - The planned share reduction will occur within three months from October 21, 2025, to January 20, 2026, through centralized bidding and block trading [1] - As of the announcement date, Ma Li holds 29,846,791 shares (6.2% of total shares), and Liu Shuqin holds 8,748,000 shares (1.82% of total shares) [1] Group 2 - In 2024, Sai Sheng Pharmaceutical reported operating revenue of 416.48 million yuan, a decrease of 12.61% compared to 2023 [2][3] - The net profit attributable to shareholders was -68.85 million yuan, a decline of 166.90% from the previous year [2][3] - The net profit after deducting non-recurring gains and losses was 11.76 million yuan, a significant improvement from -42.09 million yuan in the previous year, marking a 127.94% increase [2][3] - The net cash flow from operating activities was 135.97 million yuan, showing a substantial increase of 541.05% year-on-year [2][3]